Phase 2 Trial | Oral orexin receptor 2 agonist shows promise in narcolepsy type 1, but raises hepatotoxic concerns

Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1 – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

In a randomized trial involving patients with narcolepsy, an oral orexin receptor 2 agonist reduced sleepiness and cataplexy but had liver toxic effects. Read the full trial results: https://t.co/Go7lmQTu62

— NEJM (@NEJM) July 26, 2023